Dawson Joseph H 4

What Happened

• Joseph H. Dawson, a director of Rockwell Medical, was granted 9,633 restricted stock units (RSUs) on July 1, 2026. The award shows an acquisition price of $0.00 (standard equity grant, no cash paid).
• This is an equity award (A = Award/Grant), not a market purchase or sale — it increases potential future holdings if the RSUs vest.

Key Details

• Transaction date: July 1, 2026. Report filed with the SEC on July 6, 2026.
• Price: $0.00 per share; Shares granted: 9,633 RSUs.
• Vesting: Footnote states the RSUs vest on July 1, 2027, subject to Dawson’s continued service through the 2027 Annual Meeting.
• Reverse split adjustment: Effective 12:01 AM on July 1, 2026 the company completed a 1-for-10 reverse split; the filing and the grant amounts have been adjusted to reflect that split.
• Shares owned after transaction: The filing’s post-transaction holdings are reported adjusted for the 1-for-10 reverse split (the Form 4 reflects the post-split adjusted amounts).
• Timeliness: Filing dated July 6, 2026 for a July 1 transaction — this is later than the typical 2-business-day Form 4 window and appears to be a late filing.

Context

• These RSUs are a restricted award that will convert to actual shares only if vesting conditions (service through the 2027 Annual Meeting) are met; they do not represent immediately tradable shares.
• Awards like this are common for board compensation and are informational about insider equity alignment, but they are not the same as an insider purchasing shares on the open market.